Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Autobahn Therapeutics Inc. has closed a US$32.7 million financing to support the company's continued work in the treatment of central nervous system (CNS) disorders and the advancement of ABX-002 through phase I and into phase II proof-of-concept studies for treatment-resistant depression (TRD).
Kuria Therapeutics Inc. has closed its first fundraising round to support ongoing preclinical development activities ahead of a planned series A raise.
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
RSS
